Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CKLSF's EV-to-OCF is ranked worse than 96.03% of 1411
companies
in the Biotechnology industry
Industry Median: -3.32
vs CKLSF: 62.36
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CK Life Sciences International Holdings (OTCPK:CKLSF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CK Life Sciences International Holdings's PE Ratio (TTM) for today is calculated as:
CK Life Sciences International Holdings's share price for today is $0.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CK Life Sciences International Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CK Life Sciences International Holdings EV-to-OCF Related Terms
CK Life Sciences International Holdings EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings EV-to-OCF Chart
CK Life Sciences International Holdings Annual Data
For the Biotechnology subindustry, CK Life Sciences International Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings EV-to-OCF vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (CKLSF) has a EV-to-OCF of 61.86 as of Jul. 23, 2026. This is 85% above median its historical median of 33.43. Over the past decade, CK Life Sciences International Holdings' EV-to-OCF has ranged from 16.20 to 76.25. According to the industry distribution chart, CK Life Sciences International Holdings ranks #1355 out of 1411 companies in the Biotechnology industry, placing it in the top 96%.
Is CK Life Sciences International Holdings' EV-to-OCF too high?
CK Life Sciences International Holdings' current EV-to-OCF of 61.86 is 85% above median its 10-year median of 33.43. Over the past 10 years, this metric has ranged from a low of 16.20 to a high of 76.25. Based on the distribution chart, CK Life Sciences International Holdings ranks #1355 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #1355 out of 1411 companies for EV-to-OCF. This places CK Life Sciences International Holdings in the lower half of its industry. Historically, CK Life Sciences International Holdings' own EV-to-OCF has ranged from 16.20 to 76.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. CK Life Sciences International Holdings's current EV-to-OCF is 61.86, which is 85% above median its own 10-year median of 33.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current EV-to-OCF of 61.86. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current EV-to-OCF is 61.86, which is 85% above median its 10-year median of 33.43. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current EV-to-OCF is 61.86 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
EV-to-OCF: 61.86 (85% above median its 10-year median of 33.43)
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
